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Background: An un-commissioned randomized, double-blinded, placebo controlled clinical study was planned
using a deep sea fish oil product for pets. Seventy-seven client-owned dogs with osteoarthritis were randomly
assigned to supplement the food with either the fish oil product or corn (=placebo) oil. Our main outcome
variables were force platform variables peak vertical force (PVF) and impulse, the validated Helsinki Chronic Pain
Index (HCPI) and the use of rescue NSAIDs. Secondary outcome variables were a locomotion visual analog scale
(VAS), a Quality of life VAS, a comparative questionnaire, a veterinary assessment, owners’ final assessment of
outcome and guessing the product given.
Results: When comparing the two test groups at the end of the trial (16 weeks) there was no significant difference
in any of the main outcome variables but owners of dogs that had taken fish oil were significantly happier with the
treatment at the end visit and did significantly better at guessing what group their dogs had been in, compared to
the placebo group. When comparing variables within the fish oil group as change from baseline to trial end, there
were significant positive changes in PVF, HCPI, NSAID use, Quality of life VAS, as well as in all three scores in the
comparative questionnaire (locomotion, every-day situations, and skin & coat). There were similar positive trends in
force platform impulse and in the veterinary assessment variables, although they did not reach significance. Within
the placebo group there were significant positive changes only in the HCPI and a significant deterioration
according to veterinary assessment.
Conclusions: When compared to placebo, there was not a major statistically significant benefit in using deep sea
fish oil as a pain reliever in our study population of dogs suffering from osteoarthritis. However, the fish oil treated
patients improved significantly in many of the variables, when comparing baseline values to the study-end values
within the group, indicating a true but small relief in symptoms. Deep sea fish oil supplementation could be
considered a part of the multimodal pain relieving approach currently recommended for dogs suffering from OA,
especially for individuals that do not tolerate anti-inflammatory drugs.
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Osteoarthritis (OA) is a major cause of chronic pain in
dogs; it is estimated that 20% of the dog population in
the United Kingdom and the USA are suffering from
OA [1]. Canine hip dysplasia (CHD), elbow dysplasia
(ED) and post cruciate ligament disease OA are three
common forms of canine OA [2]. As OA rarely can be
treated, it is kept silent primarily with non-steroidal
anti-inflammatory drugs (NSAIDs), often being adminis-
tered for long periods, even years. As these may have se-
vere adverse effects, a recommendation has been made
to use more natural disease-modifying agents in the pain
management of OA, in animals and humans, alike [3,4].
To this end, more research is being conducted to find
less detrimental treatments [5].
In human medicine it has been clear since the 80’s that
fish oil helps people with rheumatoid arthritis (RA) [6-10].
The idea of treating canine OA with fish oils came from
anecdotal evidence in the late 80s, where dogs in a trial of
atopy, but with concurrent hip dysplasia, had been given
fish oil for their dermatological problem and at the same
time the owners reported a positive effect on their pets’
pain and lameness symptoms [11,12]. In spite of this, the
first randomized, controlled, blinded canine fish oil trials
on OA patients were published only in 2010 [13-16].
As the pathophysiological events associated with OA
are becoming increasingly understood, anti-inflammatory
eicosanoids are considered attractive new therapeutic
disease modifying agents that target the inflammatory
process [17]. The eicosanoids derive from three different
essential fatty acid (EFA) cascades. The first, the omega
(ω)-6 arachidonic acid (AA) cascade results in many pro-
inflammatory eicosanoids such as leukotriene B4 and pros-
taglandin E2, where at least the latter has been shown to
positively correlate with OA pain [18]. One of the other
two parallel cascades that compete with the AA cascade is
the ω-3 eicosapentaenoic acid (EPA) cascade, resulting in
more anti-inflammatory eicosanoids [19-21]. The pro-
posed anti-inflammatory working mechanisms of fish oil
lies in their high content of acids from the last section of
this EPA cascade, namely EPA and docosahexaenoic acid
(DHA). Also in dogs it has been shown that by increasing
the content of EPA or other oils from this particular
cascade, there will be partial replacement of AA in
cell membranes by EPA and DHA, which leads to a
shift from the pro-inflammatory eicosanoids that the
AA cascade forms to the anti-inflammatory eicosanoids
the EPA cascade forms [22,23]. EPA is also known to have
anti-inflammatory effects of its own; it may suppress
the production of pro-inflammatory cytokines such as
interleukin-1β and −6 and tumor necrosis factor-α [24-26].
Also, a significant reduction in activities of matrix metallo-
proteinase (MMP)-2 and −9, which contribute to cartilage
destruction, as well as a significant increase in the tissueinhibitor of MMP-2 (TIMP-2) has been recorded after
fish oil supplementation [27,28]. As dogs and cats in
the western world nowadays primarily eat commercial
foods, Remillard has even suggested that our animal
patients with chronic inflammatory diseases might either
be primary ω-3 deficient and/or ω-6 toxic, as commercial
diets often have a very high ω-6:ω-3 fatty acid ratio [29].
The purpose of the study was to test if supplementing a
basic commercial canine diet with liquid fish oil rich in
EPA and DHA, would benefit patients already suffering
from a chronic inflammatory process such as OA. We
hypothesized that the dogs taking fish oil would show an
increase in ground reaction forces, a decrease in the owner
and investigator evaluated lameness and pain scales, a de-
crease in NSAID use, and a decrease in serum AA as well
as an increase in serum ω-3 fatty acids, compared with a
control group that got corn oil as a supplement.
Results
Dogs
Two hundred and thirty dog owners returned the appli-
cation questionnaires. After an application screening,
ninety-three owners were interviewed by telephone to
get additional information and eighty-nine of these were
then invited to the first screening visit.
Six owners either never came to the baseline evaluation
or withdrew their consent so two new dogs were invited
for screening and passed. Eight dogs were excluded be-
cause of the following reasons: abnormal laboratory results
(n= 4), a Helsinki Chronic Pain Index (HCPI) under 6
(n= 1), same grade lameness in two legs (n= 2) and not
having OA (n=1). Seventy-seven dogs continued to the
medication phase. Six owners were lost to the follow-up;
four from the treatment group [owners wanted to exit
study because their dog was losing weight even after food
change (n= 1), owner did not want to comply to the study
plan (n= 1), owner did not get enough help for pain from
the rescue NSAID (n= 1), owner opted for euthanasia
(n= 1)] and two from the placebo [hemorraghic enteritis
(n= 1), owner opted for euthanasia (n= 1)]. Seventy-one
dogs finished the study; 35 dogs from the treatment group
and 36 dogs from the placebo group (Figure 1). Of the 71
dogs there were 14 mixed-breed dogs and 30 different
breeds represented: 6 Collies, 5 German Shepherd Dogs,
Golden Retrievers, and Labradors, 4 Baucerons, Bernen
Sennen Dogs, and Rottweilers and all other breeds with
1–3 dogs/breed. There were both uni- and bi-laterally
affected dogs. All dogs had either moderate or severe
radiological changes in the worst affected joint. At baseline
(W0), eight dogs were still taking NSAIDs; five in the treat-
ment group and two in the placebo group were taking 1–2
doses per month and one dog in the treatment group was
taking 3–5 tablets per week. There was no baseline bias





































New dogs invited to the
study (n=2)
Figure 1 Flow diagram through study.
Table 1 Baseline characteristics of both treatment groups
Baseline data Fish oil Placebo (corn oil) P-value
Total no of subjects (finished the study) 39 (35) 38 (36) P = 1.000
Male / female 17/22 17/21 P = 1.000
Castrated / sterilized / intact 7/15/17 10/10/18 P = 0.427
Body condition score (median, total range 1–5) 3 (2–5) 3 (2–4) P = 0.852
Mean bodyweight ± SD, kg 33.5 ± 12.0 34.2 ± 8.6 P = 0.755
Mean age± SD, years 5.6 ± 2.9 6.5 ± 3.0 P = 0.227
Food eaten at study end (beef / chicken / other) 33/5/1 31/7 P = 0.961
Hip OA (only hip OA) 34 (17) 36 (14) P = 0.431
Stifle OA (only stifle OA) 5 (1) 5 (0) P = 1.000
Elbow OA (only elbow OA) 13 (1) 13 (1) P = 1.000
Any OA+ spondylosis or vertebra-OA 8 13 P = 0.208
Duration of symptoms (median) over 2 years 1-2 years P = 0.312
Mean HCPI score at inclusion (W−2) ± SD 16.6 ± 5.8 17.4 ± 5.8 P = 0.464
Number of High (>17) / Low (0–17) HCPI in group 18/21 18/20 P = 1.000
Peak vertical force at baseline ± SD 76.7 ± 19.6 77.2 ± 20.5 P = 0.918
Impulse at baseline ± SD 9.9 ± 3.5 10.0 ± 2.9 P = 0.909
Mean Lameness VAS at baseline ± SD 3.8 ±1.9 4.5 ± 1.9 P = 0.138
Mean Quality of life VAS at baseline ± SD 3.6 ± 1.8 3.8 ± 1.8 P = 0.712
Mean Veterinary index at baseline ± SD 2.4 ± 2.4 2.5 ± 2.2 P = 0.881
Median NSAID use, first questionnaire (W−8) 0-2 x/month 0-2 x/month P = 0.317
P values are for comparison between groups: In 2 x 2 tables the exact Fisher’s tests were used, in nominal to ordinal/scale Linear-by-linear association Chi-Square
test were used.
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Nine dogs started with the sensitive rice/chicken food
while 66 started with the basic wheat/beef food. Four
more dogs changed their diet to the rice/chicken during
the trial while two dogs changed food from rice/chicken
to the basic. One dog started out on the basic, changed to
rice/chicken and then changed to Frank’s Pro Gold, which
it then ate through the rest of the study. The wheat/beef
diet gave on average 0.018 mg±0.006 (SD) (range 0.01-
0.04 mg) of ω-3 fatty acids per dogs’ kg BW and the rice/
chicken diet was very similar. The fish oil gave 110.25 mg±
5.75 (SD) predominantly EPA and DHA, and the corn
oil 1.7 mg± 0.09 (SD) (range 1.4-1.8), predominantly
α-linolenic acid (ALA), of ω-3 fatty acids, per dogs’ kg BW.
Both foods and oils were palatable: 98.4% of the dogs
that ate the basic food and 87.5% of the dogs that ate
the rice/chicken food liked it; 91.4% of the dogs that ate
the fish oil and 97.2% of the dogs that ate corn oil, liked
what they were eating. There was no statistical differ-
ence in how dogs liked the foods and the oils.
When the owners evaluated appetite, vomiting, diarrhea
and skin problems/itching every month, there were never
any significant differences between the two groups. One
dog from the placebo group suffered from hemorrhagic
enteritis. The used oil had been stored in a refrigerator as
instructed and was analyzed for contaminating bacteria
but found negative. This dog was already on the sensitive
dogs’ food as it had a history of easy diarrhea and the
owner decided to leave the study.Table 2 Primary and secondary variables per group at start a
between groups
Variable Fish oil
Baseline End of trial P-value*
PVF 76.7 ± 19.6 82.6 ± 22.6 0.021
Impulse 9.9 ± 3.5 10.2 ± 3.5 0.092
HCPI 16.1 ± 5.4 12.8 ± 6.8 <0.001
NSAID use { 1.0 ± 1.4 0.4 ± 0.8 0.017
Locomotion-VAS 3.8 ± 1.9 3.5 ± 2.1 0.489
QOL-VAS 3.6 ± 1.8 2.9 ± 1.8 0.045
Comp. mobility 26.1 ± 4.55 23.1 ± 11.0 0.021
Comp. daily chores 22.7 ± 4.7 19.2 ± 9.5 0.011
Comp. skin/hair 7.9 ± 1.1 6.9 ± 3.0 0.025
Vet. index 2.4 ± 2.4 2.1 ± 2.5 0.096
Owner final (1–5) } NA 1.3 ± 1.2 NA
Group? (1–2) £ NA 1.4 ± 0.5 NA
* = P-value of comparing start of trial to end of trial, within group.
†=P-value of comparing change from baseline to end of trial, between groups, exc
difference between the two group means at end of trial.
{=W−8 was here used as baseline, as owners were asked to not use NSAIDs at W0.
}=At the end of trial the owners answered a questions on how well the treatment
2 = quite well, 3 = to some parts, 4 = not so well, 5 = not at all.
£ =Owners guessed that their dogs were in 1 = the treatment or in 2 = the placebo
Comp. = comparative questionnaire. Values P <005 are bolded. NA= data not availCovariates are mentioned in the results only when
they were significant.
Main outcome variables
Differences between treatment groups were not signifi-
cant for any of the four main outcome variables (force
platform variables PVF and impulse, the HCPI and res-
cue NSAIDs). Results at baseline and end of trial per
group, as well as change from baseline to end of trial
both within and between groups for all variables are
shown in Table 2.
With the force platform variables the variation between
dogs was notable. When looking at the mean values of the
percentage change from baseline to end of study, no dif-
ference between treatment groups was present in either
PVF or impulse. However, when looking at the change
from baseline to end of study within the fish oil group
there was a significant change (P= 0.021) for the PVF and
a trend towards change in the impulse (P= 0.092). These
changes were not significant in the placebo group.
Within both fish oil and placebo groups, the HCPI sig-
nificantly decreased between baseline and end of trial
(P < 0.001 and P= 0.013, respectively). For a reason un-
known to us, the HCPI increased from baseline to week
four in the fish oil group.
The use of NSAIDs decreased in both groups between
W−8 and end of trial: e.g. NSAID given 3–7 days per
week decreased in the fish oil group from 17.9 to 2.9%,
and in the placebo group from 10.8 to 5.6%, respectivelynd end of trial and P-values for change within and
Placebo Between
Baseline End of trial P-value* P-value†
77.2 ± 20.5 79.3 ± 22.1 0.210 0.388
10.0 ± 2.9 10.6 ± 3.4 0.207 0.699
17.1 ± 6.4 15.0 ± 6.9 0.013 0.335
0.7 ± 1.2 0.4 ± 0.9 0.214 0.740
4.5 ± 1.9 4.0 ± 2.2 0.220 0.354
3.8 ± 1.8 3.5 ± 1.9 0.301 0.749
25.9 ± 4.1 24.1 ± 5.7 0.122 0.525
21.6 ± 4.2 20.2 ± 5.6 0.339 0.595
7.8 ± 1.6 7.5 ± 2.0 0.424 0.572
2.5 ± 2.2 2.7 ± 2.6 0.009 0.196
NA 1.9 ± 1.1 NA 0.029
NA 1.7 ± 0.5 NA 0.028
ept for the last two (“owner final” and “Group?”), where the P-value is the
corresponded to their idea of a successful treatment; 1 = corresponded fully,
group.
able.
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decrease of rescue NSAIDs was significant (P = 0.017).
NSAID use at 8 weeks before the study seemed to be
significant in explaining NSAID use during the study:
patients using more NSAIDs before the study were more
likely also to use them during the study.
Secondary outcome-variables
When comparing the opinions of the owners in the two
groups at the end of trial, there was significant differences
both in how owners considered the results to correspond
to what they had hoped for as a good treatment and in
which group they suspected their dog had been in (Table 2).
Given as quantitative percentages; 65.7% of the owners of
dogs in the treatment group were happy with the treat-
ment compared to only 38.9% in the placebo group and
60.6% of the owners that were from the treatment group
guessed that they were from the treatment group whereas
only 31.4% of the owners that were from the placebo group
guessed that their dogs were in the treatment group).
Within the treatment group, the change in the
QOL-VAS from baseline to end of trial was statistically
significant (P= 0.045), whereas this was not the case in the
placebo group. Neither groups’ changes were significant
for the lameness-VAS. Also here, the VAS-scores in
the treatment group deteriorated between baseline and
4 weeks and only after that their condition improved; then
at a higher speed than in the placebo-group.
All three comparative questions sum-scores were signifi-
cantly better at the end of study compared to baseline inFigure 2 Use of NSAIDs before the start of the trial and use of NSAIDthe treatment group: locomotion (P= 0.021), every-day
situations (P= 0.011) and skin & hair coat (P= 0.025).
These differences were not statistically significant in the
placebo group. In the every-day-situation score no covari-
ates significantly explained the change from baseline. In
the comparative locomotion- and hair coat questions,
back radiology was a significant factor in explaining differ-
ences in the sum of scores: Patients with more radiological
findings in the spine also had higher scores in the move-
ment and coat related questions.
Within the groups, the placebo dogs were assessed by
veterinarians as having significantly deteriorated in lame-
ness, jumping and walking stairs (P=0.009). The treatment
group had become better but this did not quite reach sig-
nificance (P=0.096). Although radiological findings in the
stifle or thoracolumbar spine had some influence on the
veterinary scores, the effects did not remain statistically
significant when put together to form a final model.
Serum analyzes
To test for owner compliance and to see that the product
indeed had been ingested, the amount of EFAs in plasma
phospholipids was analyzed. There was a significant in-
crease in EPA from 1.0 ± 0.08 to 6.8 ± 0.5 (P< 0.001) and
DHA from 1.5 ± 0.1 to 3.0 ± 0.2 (P< 0.001), and a decrease
in AA from 19.5± 0.4 to 14.2± 0.4 (P< 0.001) in the fish
oil group compared to a significant increase only in AA
from 19.5 ± 0.4 to 20.2± 0.4 (P= 0.030) in the placebo
group, indicating that the dogs had taken their proper
products.rescue medication during the trial.
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In evidence-based medicine, unbiased randomized con-
trolled trials are crucial in the decision-making of which
treatment to use. The results of this study suggest that
there is some benefit in feeding an ω-3 fish oil supple-
ment to dogs with OA, but that this benefit is relatively
modest. There was no statistical difference between the
fish oil and the placebo groups in any of the primary
treatment effect variables, and only in two of six second-
ary outcome variables, being the owners’ final evaluation
of the result and his guessing of the supplement given.
Therefore our hypotheses of difference in treatment ef-
fect between treatment group and placebo group failed.
However, there were several significant changes between
baseline and end of trial especially in the fish oil group,
indicating that there is some effect but that the effect is
not strong. Previous research indicates that there could
be an anti-inflammatory effect [17-21].
There are four recent canine fish oil studies; all four
were randomized, controlled, blinded but all were also
supported by an international pet food company [13-16].
Although there is no reason to suspect any industry bias
we feel that it is important that also un-commissioned
university based studies are conducted. We can, how-
ever, now conclude that our results were very similar to
the previously reported canine OA studies. Roush et al.
found 3/13 different variables (two at one single time
out of 3 possible time points) and one at two time
points, giving a significant change in 4/39 variables,
possibly indicating a very small treatment effect – or
statistical chance [13]. Their second study found no sig-
nificant differences between treatment and placebo
groups but one could see a slightly greater reduction of
lameness over time, only within the treatment group, in-
dicating a small effect [14]. The third study showed a
small but significant difference in NSAID intake between
groups, indicating a more curative effect of the ω-3 diet
[15]. The fourth study found a significant (food over
time) interaction effect in 2 of 5 of the outcome vari-
ables, between the food with least and most EPA+DHA
(0.8% and 2.9%, respectively) [16]. So far there is no
study evaluating only fish oil for OA in humans but
there are three studies evaluating fish oil with something
else for humans suffering from OA. One study using a
product containing fish oils rich in ω-3 and ω-6 fatty
acids, nettle (urtica dioica), zinc and vitamin E, showed
a big significant decrease of both NSAID use and, pain,
stiffness and function scores (WOMAC) in the treated
group, compared to the placebo group [30]. The results
were criticized in a letter to the editor where the writer
pointed out that the results presented would have been
76% more effective for pain reduction than an intra-
articular corticosteroid injection [31]. Another study
evaluated fish oil combined with lemon verbena (Aloysiatriphylla, Lippia citriodora) extract. Also here validated
scores were used (WOMAC and Lequesne) and showed
that the treatment reduced symptoms of pain and stiff-
ness significantly and improved physical function both
between groups and in the treatment group but not in
the placebo group [32]. A third study compared glucosa-
mine alone and glucosamine plus a combination of fish
oil and other ω-3 oils, where the combined group gave
significantly better results [33]. As the products used in
the human studies were different from the ones used in
the canine studies, it is of course possible that the added
nettle, lemon verbena, zinc or glucosamine might have
made these products superior. Anyway, results this
strong have not yet been published for dogs.
Different factors such as heterogeneous patient material,
ω-6: ω-3 ratio, EFA dose or duration of treatment may
have decreased the effect size, if it existed. In our study
population we found a variation in severity and location of
the OA as well as co-morbidity like spondylosis of the ver-
tebras and secondary lameness. It would be preferable that
all patients only suffered from OA in a single joint in a
single leg, especially when evaluated for ground reaction
forces using a force platform. However, all dogs with OA
start to shift weight, leading to secondary lameness in its
other legs that at times can be even worse than the initial
“worst” leg. Front leg secondary tendinitis or muscle
cramps can also introduce noise into gait evaluations. This
could be seen in the large standard deviations of the force
platform variables in our results that could not be
explained by treatment group or any of the considered
covariates. As fish oil has been shown to work on inflam-
matory factors, it is possible that the supplement will not
work on secondary non-inflammatory pain such as from
osteophytes, trigger points or cramps. This will always be
the downside of conducting clinical trials, in humans and
dogs alike. On the other hand, the upside is that heteroge-
neous group of patients mimics the real clinical situations
where we treat; the patients do not all suffer from the
same induced arthritis but have concurrent back pro-
blems, more than one leg or joint is involved and they are
not all the same size and age. In times of ethical awaken-
ing and with translational pain research emerging, it is
also much more ethical and clinically relevant to use
owner owned dogs that have the real, chronic disease and
that live a normal life with their families, than laboratory
dogs with induced arthritis.
Our serum analyses showed that the AA decreased
and the EPA and DHA increased in our fish oil group,
whereas no such change could be seen in the placebo
group, confirming that dogs had ingested the right oils.
Such changes have been reported repeatedly in dogs
after ingesting fish oil formulas [13,23,27,28,34] even
though the decrease in AA proportion has not been seen
in all human studies [21].
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was 1:14, for the corn oil it was 52:1 and in the dog food
11:1. The ratio of ω-6 to ω-3 was initially believed to be
important [35] but has now been shown to be of less im-
portance [23]. Nowadays it is recognized that it is the
absolute dose of the ω-3 and the ω-3 source used that
are more important, as the conversion rate differs de-
pending on the oil - e.g. much more vegetable ω-3 ALA
is needed for the ineffective conversion of ALA into
EPA than if you give fish oil EPA directly [23,27]. It has
both been suggested that it would be better to give more
DHA than its shorter precursors, eg. EPA [34], as well as
to give mainly EPA instead of DHA, especially for OA
patients [36]. But, as both EPA and DHA have anti-
inflammatory properties of their own and as they both
come out when fish is pressed, it might be useful to give
them in combination. Different ratios could be tested for
effect in further studies.
It is conceivable that a larger dose of the fish oil could
have given a better result. The dose of the ω-3 oils used
in the present study (90 mg EPA, 20 mg DHA and
5.4 mg ETA per kg BW) was, however, similar to the
doses that have been used in other studies: In human
adults daily doses of 1.8-3.2 g of EPA and 0.9-2.4 g of
DHA were used in studies for different inflammatory
diseases [37-39]. If a human is considered to weight
about 70 kg, the kg calculated daily doses from these
studies would be between 26–45 mg EPA and 13–34 mg
DHA per kg BW. In one canine study the researchers
wanted to try a DHA enriched fish oil formula and used
11–14 mg of EPA and 17–21 mg of DHA per kg BW
[34]. Another canine study used 48 mg of EPA and
42 mg of DHA per kg BW [28]. Other studies give the
amount of ω–3 fatty acids as g per kg food. The Hill’s
studies give the ω-3 dose as % of food on a dry-matter
basis and conclude that the test food had 3.47% ω-3 s
and the placebo food 0.11%, meaning that the test food
had an over 31-fold higher amount of total ω-3 s, com-
pared to the control [13]. Hall used 6.2 g ω-3 fatty acids
per kg of food [23]. As we do not know how much the
dogs ate in that study we can, however, not calculate the
mg/kg BW daily doses. Blonk showed that, in humans,
doses over ~1.2 g DHA/day (given as fish oil) saturates
the plasma DHA concentration and further increase of
given DHA increase the plasma concentration only in-
crementally [40]. This has not to our knowledge been
studied in dogs. Hall concluded that 175 mg of DHA/kg
BW/day was needed to attain maximum plasma levels of
DHA in dogs [23]. As EPA will change into DHA in the
EPA cascade, it is however unclear how much of EPA
and DHA combined is needed to achieve maximum
plasma levels. In fish oil the EPA concentration is usually
about 60% and the DHA 40% [41]. In the product we
used the DHA was about 22% of the EPA amount.Although we had a significant increase in both DHA
and EPA in our end-of-trial samples in the fish oil group,
it is possible that we did not come up to the maximum
plasma levels. Therefore we cannot say if a bigger dose
still would have benefitted the outcome. However, as our
oil contained only fish derived EPA and DHA and as
there was a big difference in the ω-6:ω-3 ratio between
the fish oil and the placebo, we think that our dose and
ratio used led to at least some positive results. As EPA,
DHA and other EFAs from the EPA cascade have been
shown to have anti-inflammatory properties, this sup-
ports the clinically positive, although mild, results seen
in our treatment group and not in the placebo group.
Our study period was 16 weeks. Less than 12 weeks
have been considered too short in human studies [42].
We could see a small worsening in the treatment group
at week four based on HCPI and the VASs. This has not
been reported before. It is hard to say why this worsen-
ing occurred, as the owners otherwise did not comment
on anything being negative in the same time period.
After this the pain and lameness seemed to decrease and
QOL to increase at a slightly higher rate in the treat-
ment group than in the placebo group, so without the
sudden exacerbation at week four or with a longer fol-
low-up, a significant difference between treatment group
could have been achieved favoring the treatment group.
However, with the data at hand, no significance differ-
ence could be detected.
Conclusion
When compared to corn oil (placebo), there was not a
statistically significant benefit in using deep sea fish oil
as a pain reliever in our study population of dogs suffer-
ing from osteoarthritis. However, when comparing base-
line values to the study-end values within the group
during the 16 week study, the fish oil treated patients
improved significantly in many of our outcome variables
indicating a true, but small, relief in pain symptoms.
During the same time there was nearly no effect within
the placebo group. As other studies have shown a similar
effect, we feel we can recommend fish oil e.g. for




The study was designed as a randomized double-blind
clinical trial with a treatment group and a negative
(=placebo) control group, using the CONSORT guide-
lines [43]. Owners were asked not to give their dogs
NSAIDs or corticosteroids for 15 days prior to the study
and not to use Na-pentosan polysulphate (CarthrophenW,
Biopharm Pty. Ltd., Australia) for 30 days prior to the
study.
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dog owners that contacted us first completed a question-
naire. Based on this and a following telephone interview
conducted by a secretary blinded to the randomisation
list, dogs were invited to the pre-baseline screening visit,
two weeks before the baseline (W−2). At this screening
visit the dogs were assigned into groups in order of ar-
rival using a computer-generated 4 block random list. A
high (over 17) or low (17 or lower) level of pain accord-
ing to the Helsinki chronic pain index (HCPI) [44-46],
and normal or sensitive diet were stratified for. The
owners answered a second questionnaire and dogs were
evaluated by a veterinarian, they were customized to the
force platform and blood samples were taken and ana-
lyzed for inclusion or exclusion. All dogs were sedated
using medetomidine chloride (DorbeneW, Vetcare Oy,
Salo, Finland) at 20–80 μg/kg BW and propofol (Propo-
clearW, Scanvet, Parola, Finland) at 2 mg/kg BW and
radiographs were taken of the dogs’ hips, lateral lumbar
spine, knees and elbows, and other joints if needed.




































W8 8 weeks after
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ouor radiographs showed that they were not eligible for the
study. All dogs started the new diet after this first visit.
There were two evaluation visits to the clinic: the
baseline visit (at week zero =W0), after which the dogs
started with the product or the placebo and the “end of
trial”-visit (at week 16 =W16), when products had been
taken for 16 weeks. For ethical reasons all owners were
also given an NSAID that could be used in case of severe
pain; 10 tablets of 227 mg firocoxib (PrevicoxW, Merial
Norden A/S, Denmark) in normal packaging, with dos-
ing instructions (5–10 mg / kg BW, once daily). More of
this rescue medication was supplied upon request during
the whole study period. At both evaluation visits the
owners answered questionnaires, the dogs were evalu-
ated by a veterinarian and tested on gait analysis equip-
ment, and blood samples were taken.
All evaluators (veterinarians and owners) and all tech-
nical assistants were blinded. Owners of the dogs were
required to sign informed consent forms. They could
drop out of the study without giving a reason at any time.
The study protocol was approved by the Ethics Committeed evaluations done during study period
utcome variables, other tests and evaluations
uestionnaires At clinic
escriptive data. Questionnaire
pain items, including HCPI.
meness and QOL VAS. Use of
AIDs / adjuvant analgesics.
uestions about unclear answer
the inclusion questionnaire
uestionnaire on pain items,
cluding HCPI. Lameness and
OL VAS. Use of NSAIDs / adjuvant
algesics.
Thorough veterinary
evaluation + lameness, jumping
and stairs on video. PVF, Impulse.
Blood samples (inclusion).
Radiographs.
uestionnaire on pain items,
cluding HCPI. Lameness and
OL VAS. Use of NSAIDs / adjuvant
algesics.
Veterinary evaluation: Lameness,
jumping and stairs on video. PVF,
Impulse. Blood samples.
uestionnaire on pain items,
cluding HCPI. Lameness and QOL
S. Use of rescue analgesic. Adverse
fect questions. Comparative
estions: locomotion, every-day
uations and skin and hair-coat.
me as at W4.
me as at W4.
uestionnaire on pain items, incl.
PI. Lameness and QOL VAS. Use
rescue analgesic. Adverse effect
estions. Comparative questions:
comotion, every-day situations and
in and hair-coat. Final assessment of
tcome. Guessing group.
Veterinary evaluation: Lameness,
jumping and stairs on video. PVF,
Impulse. Blood samples.
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at the Small Animal Hospital of the University of Helsinki.
Dogs
Dogs were recruited for the study through advertise-
ments in daily papers, dog magazines, pet stores, veter-
inary clinics and dog parks. Patients were considered
eligible for inclusion if they had clinical signs and
a radiographic diagnosis of hip, elbow and/or knee
osteoarthritis. The owner had to describe at least three of
the following signs as being frequent: difficulty in lying
down and/or in getting up from a lying position, difficulty
in jumping or refusing to jump, difficulty in walking up or
down stairs, or definite lameness. The dogs had to be over
18 kg (because of the force platform analysis), over 1 year
of age and have a HCPI of more than 6. Exclusion criteria
were if the dogs were pregnant or lactating, had neuro-
logical deficits, lameness from acute articular infection,
recent trauma or, if the owner would not comply with
changing the dog’s diet and/or give the supplement daily.
All dogs lived with their owners during the whole study
period and came in only for the evaluations. One change
in eligibility criteria was made already before baseline:
As some owners felt they could not leave out the
NSAIDs two weeks prior to the study it was decided
that these dogs anyway should be left in the study.
Also, as owners were told not to give NSAIDs or
other analgesics two weeks prior to the baseline visit,
we could not use the “NSAID use at the baseline visit” asTable 4 Fatty acid composition of the supplements and the fe

















Total unknown FA 2.50
LA= Linolenic acid, DPA=Docosapentaenoic acid, PA=Palmitic acid, PO=Palmitolei
MUF=Monounsaturated fat, SAF= Saturated fat. For rest of the FA nomenclature, sea prior to trial medication variable; instead we used the
info on NSAID use that we received from the owners the
first time we asked them, at W−8. The used variable would
therefore be the change in NSAID use between the first
questionnaire and the trial-end visit.
Food and test products
There were two commercial foods available, either a
basic wheat/beef (Royal CaninW Croc) or a rice/chicken
sensitive formula (Jahti & VahtiW lamb and rice) dry dog
food. Both of the products had similar nutritional and
energy values and low ω-3 oil content (1.2-1.6 g ω-3 per
kg of food), with an ω-6:ω-3 ratio of 11:1. The rice/
chicken dry food contained no wheat, no soy, no beef,
no preservatives, no artificial colors and could be used
for dogs sensitive to food proteins and/or additives. Nei-
ther food contained ingredients have been found to have
positive effects on OA.
The supplement used in this study was a pharmaceut-
ically cleaned dense deep sea fish oil (DoilsW joints;
Nutraceuticoils, Belgium) with low water content and
added vitamin E. The fish oil contained 450 mg EPA,
100 mg DHA and 27 mg eicosatetraenoic acids (ETA)
per ml, or a total of 63.6% ω-3 s. The fish oil product
was supplied by the manufacturer together with a placebo
corn oil with fish smell in identical containers. The
placebo (corn oil) contained no EPA, DHA or DPA, and
only 1% of other ω-3 s (mainly ALA) (Table 4). The pro-
ducts were organized into sequentially numbereded

















c acid, ST= Steric acid, OL=Oleic acid, PUFA=polyunsaturated fatty acids,
e abbreviations.
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involved in the rest of the study. The dose was the same
for all dogs regardless of group; 1 ml of fish or corn oil
per 5 kg of dog body weight (BW).
Owner assessment
The owners answered multi-dimensional questionnaires
about their dogs at seven different times: Six weeks before
the first screening visit (W−8 = 8 weeks before baseline),
during the screening visit (W−2 ), at the baseline visit
(W0), at home once a month between visits (W4, W8, and
W12) and at the end of trial-visit (W16). The first W−8
questionnaire was either downloaded from the Internet or
sent to the owners and thereafter returned to us for inclu-
sion consideration. The second and third questionnaires
were also pre-treatment baseline questionnaires, com-
pleted at the first two visits (pre-baseline screening W−2
and baseline W0). The fourth to sixth questionnaires were
given to the owners at the hospital at W0, to be completed
at home and sent back in pre-stamped return envelopes.
The last questionnaire was completed at the hospital, just
before the “end of trial”-visit (W16).
The first questionnaire included descriptive questions
such as gender, age, diagnose, used treatments etc. and
these were only asked once. The following three parts
were then included in every round of data collection: (i)
Of a total of 19 pain related descriptive scale (0–4) ques-
tions on attitude, behaviour, and locomotion, 11 ques-
tions formed the owner-assessed HCPI, as described
previously [44-47]. (This index now has a new English
translation that is closer to the Finnish original; the
HCPI-E2, but the validated original remains the same
[47,48]). (ii) Two 10-cm VAS: one for lameness and the
other for quality of life (QOL). The end of the VAS lines
to the left represented no lameness whatsoever and the
best possible QOL and to the right, the worse possible
lameness or the worse possible QOL. (iii) A question
about given NSAIDs or adjuvant analgesics before the
trial start or about given rescue medication during the
trial used the following scale: “during the last four weeks
analgesia was given 1 =not at all, 2 = 1–2 times per
4 weeks, 3 = about once a week, 4 = about 3–5 times a
week, 5 = daily/almost daily”.
All questionnaire data collected after the start of trial
(W4 to W16) included additional parts: (iv) Questions
about possible adverse reactions to treatment; change in
appetite, vomiting, diarrhoea and atopic skin reactions
and (v) 18 comparative questions summed together
under three categories: “locomotion”, “every-day situa-
tions” or “skin & hair coat”. These questions all used a
standard 5-point relative response: “Compared to before
the beginning of this trial, the dog’s (item) is now.
1 =much better, 2 = a bit better, 3 = the same, 4 = a bit
worse, 5 =much worse”. At the end of trial visit theowners also answered questions about (vi) how well the
treatment corresponded to their idea of a successful
treatment; 1 = corresponded fully, 2 = quite well, 3 = to
some parts, 4 = not so well, 5 = not at all, and (vii) if they
thought their dog had been in the 1 = treatment or in
the 2 = placebo group.
Veterinary evaluation
At the screening visit (W−2) a more thorough clinical,
orthopaedic, and neurological examination was per-
formed for inclusion or exclusion by an orthopaedic
surgeon specialized in canine pain. The same surgeon made
a basic clinical, orthopaedic and neurological evaluation
and assessed lameness, jumping, and walking stairs at
W0 and W16, using 0–4 descriptive scales that then
were summed to a continuous vet-assessment score with a
minimum of 0 (no difficulties whatsoever) and a maximum
of 12 (more or less non-ambulatory).
Gait analysis
Gait was analysed using a force platform at W0 and
W16. The force platform gait analysis (Kistler force plat-
form, Type 9286, Kistler Instrumente AG Winterhur,
CH-8408, Switzerland) assesses weight bearing of two
limbs at the time. The force platform was submerged
into the concrete floor so that the platform and floor
surfaces were on the same level. The floor was then cov-
ered with a 5-mm-thick rubber mat that extended from
7 m before to 7 m after the platform, forming a 14-m
walkway. A hole was cut in the mat over the force plat-
form and a 3-mm gap was left between the force plat-
form mat and the rest of the mat. The signal from the
platform was processed and stored using a computer-
based software program, and velocities and acceleration
were determined by three photoelectric cells placed
exactly 1 m apart and a start-interrupt timer system
(Aquire 6.0, Sharon Software Inc., DeWitt, USA).
Dogs guided by their owners trotted over the walkway
from right to left. The speed was one comfortable for
each dog in trot and had to be in the same range
(± 0.5 m/s) for the dog each time the test was per-
formed. Acceleration/braking was kept < 0.5 m/s/s and
contact had to be made with the platform first by the
forelimb and shortly after with the hind limb of the same
side for the evaluation to be valid. Three valid measure-
ments for each side and for each visit were then chosen
by a blinded assistant according to speed, acceleration,
and with no interferences, such as gait abnormalities or
extra body movements. These ground reaction forces
were normalized for each dog’s body weight and mean
peak vertical force (PVF) and mean vertical impulse
were used as variables [49].
Only measurements from the most severely affected
leg at baseline (W0), based on clinical evaluation and
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in both analyses.
Blood samples
Blood samples were collected from the dogs at each
visit. To test inclusion at the pre-baseline screening visit
(W−2) creatinine, glucose, serum alanine aminotransferase,
alkaline phosphatase, total protein, and cholesterol were
analyzed. When cholesterol was high, T4 and TSH were
also analyzed. At baseline (W0) and at the end of the
trial (W16) blood urea nitrogen, creatinine, glucose, serum
alanine aminotransferase, alkaline phosphatase, total protein,
albumin, cholesterol, triglycerides, and fatty acids were
analyzed. The total fatty acid analyses, gene-expression
analyses and parameters of inflammation and oxidative
stress will be reported separately.
Outcome variables
Our four main outcome variables were force platform
variables PVF and impulse, the validated HCPI and the
use of rescue NSAIDs. The six secondary outcome vari-
ables were owners’ locomotion visual analog scale (VAS),
quality of life (QOL-) VAS, comparative questionnaires,
the veterinary assessment score, final assessment of out-
come and guessing of group.
Statistical analysis
The number of dogs needed in each group was calculated
for a two-tailed test (Fisher) based on a human trial of fish
oils for rheumatoid arthritis [10] and a canine OA study
[50], giving 32 and 21 dogs per group, respectively, when
using statistical power of 08 and allowing for a 5% alpha
error. As there often is at least 10-20% fallout it was
decided to start with 35–40 dogs per group.
Change from baseline measurements to end of trial
were used as the response in all of the fitted models, ex-
cluding use of rescue NSAIDs. Covariates possibly influ-
encing the outcome were determined beforehand. These
14 variables included age, sex, bodyweight at baseline,
used diet, use of pain medication before the study, dur-
ation of symptoms, HCPI-score at baseline, body score
condition, sterilization/castration and radiology evalua-
tions of hip, knee, back, elbow and lumbo-sacral area.
As the weight of the dog is essential in evaluating
change in force platform variables a percentage change
from baseline was used as a response in the statistical
modeling.
The force platform variables were analyzed using
ANOVA and ANCOVA-models. The effects of the covari-
ates were evaluated with ANOVA-models, where only the
covariate at issue was used as an explanatory variable. The
group effects were evaluated with ANCOVA-models,
where the explanatories consisted of treatment group and
the significant covariates were modeled ahead.With HCPI-score direct change from baseline was used
as the response and was modeled with a RMANCOVA-
model. First the effects of the covariates were modeled
with RMANCOVA-models, where the explanatories con-
sisted of the covariate in issue, visit and the baseline-value
of the response. Patient was used as a random variable.
The same kind of modeling was then constructed
for determining the treatment group differences. The
model included treatment group, visit, baseline-value
of the response, an interaction of group and visit
and the possibly significant beforehand evaluated
covariates as fixed factors and patient as a random
factor. Pair-wise comparisons were calculated from the
model for interesting comparisons.
Differences in the use of rescue NSAIDs were evalu-
ated with subject specific cumulative logit-models for
repeated measures. The modeling was done for a re-
classified variable (3 classes), because the frequency in
the higher classes was limited. Again the effects of the
covariates were modeled first. The fitted cumulative
logit-model had visit, use of NSAIDs 8 weeks before the
study and the covariate at issue as fixed factors and pa-
tient as a random factor. Because of the same reason of
too few answers per values, previous use of NSAIDs was
also recoded to only three classes, so that classes
“Never” and “1-2 times a month” as well as classes “3-5
times a week” and “Almost daily” were put together.
Class “Once a week” remained unchanged. The differ-
ences between treatment-groups were evaluated with the
same kind of cumulative logit-model, where group, visit,
use of NSAIDs eight weeks before the study, interaction
of group and visit and possibly significant covariates
were used as fixed factors and patient as a random fac-
tor. As the owners had been asked to leave out NSAIDs
at baseline, the time point W−8 was here used as “base-
line”, to which the end of trial was compared to.
Five of the secondary outcome variables were modeled
with RMANCOVA-models (excluding veterinary assess-
ment score). The same kind of modeling was applied
here as with the HCPI-score. Veterinary assessment
score was analyzed with an ANCOVA-model, as the as-
sessment had been conducted only at baseline and in the
end of study. The same kind of model was applied to the
veterinary assessment score as to the force platform
variables.
The owners’ final thoughts on the trial as well as the
fatty acid concentrations in the serum samples at W0
and W16 were compared between groups using the inde-
pendent t-test. Changes in fatty acid concentrations
within the groups were calculated using the Wilcoxon
rank test.
P-values < 0.05 were considered to be statistically sig-
nificant and significance levels two-sided. All statistical
analyses were done using two different software (SASW
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Cary, NC, USA and SPSS 18.0 for Windows, SPSS Inc.
Chicago, IL, USA).
Abbrevations
AA: Arachidonic acid, an ω-6 FA; ALA: α-linolenic acid, an ω-3 FA;
ANCOVA: Analysis of covariance; ANOVA: Analysis of variance; BW: Body
weight; CHD: Canine hip dysplasia; CONSORT: Consolidated standards of
reporting trials; DHA: Docosahexaenoic acid; DPA: Docosapentaenoic acid, an
ω-3 FA; ED: Elbow dysplasia; EFA: Essential fatty acids; EPA: Eicosapentaenoic
acid; ETA: Eicosatetraenoic acid, an ω-3 FA; FA: Fatty acid; HCPI: Helsinki
Chronic Pain Index; MMP: Matrix metalloproteinase; NSAID: Non-steroidal
anti-inflammatory drug; OA: Osteoarthritis; ω: Omega; PVF: Peak vertical force;
QOL: Quality of life; RA: Rheumatoid arthritis; RCT: Randomized clinical trial;
RMANCOVA: Repeated measures analysis of variance; SD: Standard deviation;
TIMP: Tissue inhibitor metalloproteinase; VAS: Visual analog scale; W-x: x
weeks before baseline; W0: Baseline; Wx: x weeks after baseline.
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